首页> 外文期刊>Nature >A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition
【24h】

A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition

机译:细胞身份转换允许残留的BCC幸免于刺猬通路抑制

获取原文
获取原文并翻译 | 示例
           

摘要

Despite the efficacy of Hedgehog pathway inhibitors in the treatment of basal cell carcinoma (BCC)(1) , residual disease persists in some patients and may contribute to relapse when treatment is discontinued(2). Here, to study the effect of the Smoothened inhibitor vismodegib on tumour clearance, we have used a Ptch1-Trp53 mouse model of BCC3 and found that mice treated with vismodegib harbour quiescent residual tumours that regrow upon cessation of treatment. Profiling experiments revealed that residual BCCs initiate a transcriptional program that closely resembles that of stem cells of the interfollicular epidermis and isthmus, whereas untreated BCCs are more similar to the hair follicle bulge. This cell identity switch was enabled by a mostly permissive chromatin state accompanied by rapid Wnt pathway activation and reprogramming of super enhancers to drive activation of key transcription factors involved in cellular identity. Accordingly, treatment of BCC with both vismodegib and a Wnt pathway inhibitor reduced the residual tumour burden and enhanced differentiation. Our study identifies a resistance mechanism in which tumour cells evade treatment by adopting an alternative identity that does not rely on the original oncogenic driver for survival.
机译:尽管Hedgehog途径抑制剂可治疗基底细胞癌(BCC)(1),但仍有部分患者残留疾病,如果中止治疗则可能导致复发(2)。在这里,为了研究平滑化抑制剂vismodegib对肿瘤清除的作用,我们使用了Btc3的Ptch1-Trp53小鼠模型,发现用vismodegib治疗的小鼠具有静止残留的肿瘤,这些肿瘤会在停止治疗时再生。分析实验表明,残留的BCC会启动一个转录程序,该程序与小泡间表皮和峡部干细胞的转录程序非常相似,而未经处理的BCC则更类似于毛囊隆起。这种细胞身份的转换是通过主要是允许的染色质状态,伴随着快速的Wnt途径激活和超级增强子的重新编程来驱动参与细胞身份的关键转录因子的激活而实现的。因此,用vismodegib和Wnt途径抑制剂治疗BCC减少了残留的肿瘤负荷并增强了分化。我们的研究确定了一种耐药机制,其中肿瘤细胞通过采用不依赖原始致癌驱动程序来生存的替代身份来逃避治疗。

著录项

  • 来源
    《Nature》 |2018年第7727期|429-433|共5页
  • 作者单位

    Genentech Inc, Dept Mol Oncol, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA;

    Genentech Inc, Dept Mol Oncol, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA;

    Genentech Inc, Dept Bioinformat & Computat Biol, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA;

    Genentech Inc, Dept Translat Oncol, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA;

    Genentech Inc, Dept Mol Oncol, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA;

    Genentech Inc, Dept Res Pathol, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA;

    Genentech Inc, Dept Translat Oncol, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA;

    Genentech Inc, Dept Mol Oncol, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号